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Assessment of a polygenic hazard score
for the onset of pre‑clinical Alzheimer’s disease
Michael Vacher1,2,3*, Vincent Doré4,5, Tenielle Porter2,3,6, Lidija Milicic2,3, Victor L. Villemagne2,7,
Pierrick Bourgeat8, Sam C. Burnham2,4, Timothy Cox4, Colin L. Masters9, Christopher C. Rowe5, Jurgen Fripp8,
James D. Doecke2,8 and Simon M. Laws2,3,6

Abstract: Background: With a growing number of loci associated with late-onset (sporadic) Alzheimer’s disease (AD),
the polygenic contribution to AD is now well established. The development of polygenic risk score approaches have
shown promising results for identifying individuals at higher risk of developing AD, thereby facilitating the development of preventative and therapeutic strategies. A polygenic hazard score (PHS) has been proposed to quantify
age-specific genetic risk for AD. In this study, we assessed the predictive power and transferability of this PHS in an
independent cohort, to support its clinical utility.
Results: Using genotype and imaging data from 780 individuals enrolled in the Australian Imaging, Biomarkers and
Lifestyle (AIBL) study, we investigated associations between the PHS and several AD-related traits, including 1) crosssectional Aβ-amyloid (Aβ) deposition, 2) longitudinal brain atrophy, 3) longitudinal cognitive decline, 4) age of onset.
Except in the cognitive domain, we obtained results that were consistent with previously published findings. The PHS
was associated with increased Aβ burden, faster regional brain atrophy and an earlier age of onset.
Conclusion: Overall, the results support the predictive power of a PHS, however, with only marginal improvement
compared to apolipoprotein E alone.
Keywords: Alzheimer’s disease, Polygenic hazard score, Brain atrophy, AD onset

Introduction
The ε4 allele of the apolipoprotein E (APOE) gene is the
strongest genetic risk factor for late onset AD [1]. However, polygenic or oligogenic [2] contributions to AD
are now widely acknowledged. In recent years, genome
wide association studies (GWAS) and next-generation
sequencing efforts have facilitated the identification of
a number of disease-onset-associated single nucleotide
polymorphisms (SNPs) with much smaller effect size
Data used in the preparation of this article was obtained from the Australian
Imaging Biomarkers and Lifestyle study (AIBL).
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[3, 4]. Collectively, these genetic variations could make
a significant contribution to age-at-onset AD risk. The
combined effect of these inherited genetic variations
can be quantified and expressed as a polygenic risk score
(PRS). The development and validation of a reliable PRS
for AD could contribute to solving a major public health
challenge by identifying the age-at-onset of individuals at high risk of developing the disease and therefore
enable early screening and preventive therapies [5]. Typically, PRSs are constructed as the weighted sum of allele
counts, where the weights correspond to the effects (β
coefficients) of each SNP, extracted from a SNPs-disease
association analysis (e.g. logistic regression for casecontrol studies) [6]. The development of PRSs for age-atonset of AD have demonstrated promising results with
prediction capabilities showing over 80% accuracy in
some cases [7, 8].
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A polygenic hazard score (PHS) approach has also been
developed for AD [9]. This PHS goes beyond AD risk
prediction by providing estimates of individual age-specific risk for developing AD. Moreover, the PHS has been
shown to be associated with Aβ-amyloid (Aβ) accumulation, accelerated cognitive decline and neurodegeneration in susceptible brain regions. In this study we aim to
assess the useability and replicability of PHS in an independent cohort.

Materials and methods
Sample population

The study used data from the Australian Imaging, Biomarkers and Lifestyle (AIBL) cohort, of which the design,
enrolment process, neuropsychological assessments and
diagnostic criteria have been previously described [10].
Of the 1572 participants enrolled in the AIBL study, we
restricted the analysis to individuals having both genotype and imaging data available (N = 780). Longitudinal
data was collected every 18 months over multiple years
(mean = 4.8 years, SD = 2.1). Participants were classified
as those with Mild Cognitive Impairment (MCI) [11] or
AD [12] when the clinical criteria for diagnosis were met.
In the absence of these features a classification of Cognitively Normal (CN) was given by a clinical review panel,
blinded to Aβ-PET status (see below). Ethics approval for
the AIBL study and all experimental protocols was provided by Austin Health, St Vincent’s Health, Hollywood
Private Hospital and Edith Cowan University. All experiments and methods were carried out in accordance with
approved guidelines and regulations and all volunteers
gave written informed consent before participating in the
study.
MRI and PET imaging

All subjects underwent a 3 T MRI and Aβ-PET imaging. T1 MPRAGE MRI was obtained at 3 T using the
Alzheimer’s Disease Neuroimaging Initiative (ADNI)
magnetization-prepared rapid gradient echo (MPRAGE)
protocol, with in-plan resolution of 1 × 1 mm and 1.2 mm
slice thickness. Freesurfer was used to estimate all cortical volumes from the T1 [13]. All volumes were corrected
for age and ICV using a regression approach and reference population composed of healthy subjects (CN, Aβ
negative, MMSE> 28, CDR = 0, APOE non-ε4). Left and
right volumes were averaged.
Aβ-PET imaging was performed with one of five
radiotracers: [11C]-PiB, [18F]-flutemetamol (FLUTE),
[18F]-florbetapir (FBP), 
[18F]-florbetaben (FBB), and
18
[ F]-NAV4694 (NAV). A 20- minute acquisition was performed 50 minutes post-injection of PiB, NAV and FBP,
and 90 minutes post-injection of FLUTE and FBB. Due to
the difference in SUVR dynamic ranges of each Aβ tracer,
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the Centiloid (CL) scale was used to provide a standard
scale for Aβ-PΕΤ quantification [14], with 0 representing
the typical Aβ-PΕΤ in young controls, and 100 the typical Aβ-PET in mild AD patients. Values equal to or above
20 CL were considered representative of abnormal levels
of Aβ deposition [15]. CL were generated using CapAIBL
software [14] and estimated in three regions of interest
(whole neocortex, frontal and posterior cingulate). CL
values were also projected onto the individual cortical
surface and then transferred to a cortical atlas where statistical analyses were performed [16].
Cognitive scores

All AIBL participants complete a battery of neuropsychological tests as previously described [10]. The resulting
data were used to calculate cognitive composite scores to
assess recognition memory, executive function and episodic recall memory. Briefly, the composites were computed by standardising the outcome measure for each
neuropsychological test to be included, using the baseline
mean and standard deviation for the cognitively normal
sample, then averaging those standardised scores. Each
composite consists of the following tests; recognition
memory (California Verbal Learning Test Second Edition
and Rey Complex Figure Test), executive function (Controlled Oral Word Association Test and Category Switching), and episodic recall memory (California Verbal
Learning Test Second Edition, Logical Memory II, and
Rey Complex Figure Test) (Harrington reference). Clinical Dementia Rating (CDR) sum of boxes (CDRSB) score
was also used to assess clinical progression.
Age of onset definition

The age of onset of abnormal levels of amyloid deposition was determined as follows: First a progression curve
giving for Aβ-amyloid deposition as a function of disease
progression time was constructed as described in [17,
18]. Then, the participants’ age of onset was estimated
by using the progression curve to calculate the elapsed
time between a participant passing the CL threshold
and reaching their mean longitudinal Aβ-amyloid levels.
Finally, this value was subtracted from their mean longitudinal age to get the age at onset.
Genetic data and Polygenic hazard score

Genome wide genetic data was ascertained from the
OmniExpressHumanExome+
BeadChip
(Illumina,
USA) as previously described [10]. A polygenic hazard
score was then derived from this genetic data for each
individual following the methodology described previously [9]. Briefly, the approach consists in three steps.
First, a list of 1854 SNPs implicated with AD (p-values
< 10− 5) was extracted from the published summary
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statistics (p-values and odds ratios) generated by the
IGAP consortium [4]. Second, a forward stepwise regression to identify a subset of 31 SNPs, in addition to the
two APOE variants, that were associated with AD age
of onset. Finally, for each patient, a polygenic hazard
score predicting the individual’s risk of developing AD,
given their polygenic profile and age was derived. In the
analyses we assessed the PHS as a continuous measure,
quantifying individual risk for AD, and as a dichotomous
variable (high and low). To directly replicate the findings
from Tan et al. [19], we used the same grouping method,
defining high PHS by 1 standard deviation (SD) above the
mean and low PHS by 1 SD below the mean (Supplementary Fig. 1).

Association with longitudinal cognitive decline

Statistical analyses
Association with cross‑sectional Aβ deposition

This model was used to investigate the association
between PHS and cognitive decline and clinical progression rate (represented as Δc) across four measures: recognition, executive function, episodic recall and CDR-SB. In
this model, Time represented the number of years since
the baseline visit. The APOE term indicated the presence/absence of APOE ε4 allele, encoded as a binary
variable (0 = no ε4 allele, 1 = 1 or 2 ε4 alleles) and the
term (1| Patient) corresponded to the random intercept.
Continuous variables were centred and scaled in all the
analyses. Further, to assess the original model and limit
potential over-specification, we used a stepwise variable
selection approach (backward selection) and identified
a reduced model based on superior model fit (Akaike
information criterion).

We used linear regression to investigate the relationship
between PHS and regional brain Aβ deposition at baseline. Three main areas were investigated: neocortical, frontal cortex and posterior cingulate. In this cross-sectional
analysis, we controlled for age, gender, level of education
in years and APOE ε4 status (0 = no ε4 allele, 1 = 1 or 2 ε4
alleles). To evaluate the contribution of PHS and APOE
ε4 status in the linear regression, we used likelihood ratio
tests to compare models with and without these terms.
To further assess the association between PHS and
Aβ deposition, beyond the role APOE, we performed
the same analysis in two sub-cohorts containing exclusively APOE ε4 carriers (N = 278; CN = 161, MCI = 58,
AD = 59) and non-carriers (N = 502; HC = 412,
MCI = 66, AD = 24). In these subsequent analyses, we
used the same linear regression, however, we did not
control for APOE ε4 status due to the lack of variation in
these sub-populations. All the results were adjusted for
multiple comparisons using false discovery rate (FDR).
The same analysis was performed at a vertex level on a
template cortical surface.
Association with regional brain atrophy

We used linear mixed-effects models to evaluate the
relationship of PHS with longitudinal volume change in
33 regions of interest from the Desikan-Killiany atlas in
Freesurfer [20]. As volumes were previously controlled
for intra-cranial volume (ICV) and age using a healthy
sub-population we only controlled for gender, level of
education in years and APOE ε4 status (0 = no ε4 allele,
1 = 1 or 2 ε4 alleles). In these analyses, we also controlled
for sex, education, and APOE status. We then examined
the simple effects by comparing slopes of volume loss
over time for individuals at high (+ 1 SD) and low (− 1
SD) levels of PHS [19, 21].

For comparative purposes, we used the same linear
mixed effects models as described in the original Desikan
paper [19]. The only deviation made from this model was
the use of the CL value from the frontal cortex instead of
the standard uptake volume ratio (SUVR). Therefore, the
final linear mixed effect model was defined as follows:

Δc = 𝛽0 + 𝛽1 PHS ∗ Time + 𝛽2 Centiloid(fc)
∗ Time + 𝛽3 enthorinal cortex volume
∗ Time + 𝛽4 Baseline Age ∗ Time + 𝛽5 Sex
∗ Time + 𝛽6 Education
∗ Time + 𝛽7 APOE ∗ Time + (1|Patient)

Association with age of onset of abnormal levels of Aβ
deposition

Cox proportional hazards models of survival were performed to compare the time taken to reach abnormal
levels of neocortical Aβ between participants with low
versus high PHS scores (threshold at 1.04), adjusted baseline age, gender and years of education. The definition for
survival time was the number of years between birth and
a) having a PET scan indicating abnormal levels of Aβ
(classed here an event, age of onset), b) withdrawing from
the study (censored), or c) the last completed follow-up
examination without an event (censored). For some individuals it was necessary to impute the date at which their
Aβ levels became abnormal as previously published [22].
The age at which 50% of the cohort (median age) reached
abnormal levels of Aβ, was reported.

Results
Demographics

The study was conducted on a cohort of 780 participants enrolled in the AIBL study [23] (422 females,
358 males). Population demographic information is
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Table 1 Population characteristics
CN (N = 573)

MCI (N = 124)

AD (N = 83)

P-value

Female

318 (55.5%)

56.0 (45.2%)

48.0 (57.8%)

0.0859

Male

255 (44.5%)

68.0 (54.8%)

35.0 (42.2%)

Mean (SD)

72.9 (6.12)

75.6 (7.13)

75.0 (7.85)

Median [Min, Max]

72.7 [60.0, 93.6]

76.3 [56.1, 95.4]

74.8 [57.8, 93.2]

Absent

412 (71.9%)

66.0 (53.2%)

24.0 (28.9%)

Present

161 (28.1%)

58.0 (46.8%)

59.0 (71.1%)

0–6

1.00 (0.2%)

1.00 (0.8%)

2.00 (2.4%)

7–12

41.0 (7.2%)

17.0 (13.7%)

11.0 (13.3%)

Sex

Age (years)
< 0.001

APOEε4
< 0.001

Education (years)

9–12

213 (37.2%)

50.0 (40.3%)

29.0 (34.9%)

13–15

118 (20.6%)

22.0 (17.7%)

20.0 (24.1%)

15+

200 (34.9%)

34.0 (27.4%)

21.0 (25.3%)

Mean (SD)

0.0271 (0.763)

0.415 (0.967)

0.847 (0.941)

Median [Min, Max]

−0.178 [−1.60, 2.59]

0.162 [−1.26, 3.12]

1.01 [−1.06, 2.91]

0.0148

PHS
< 0.001

P values determined by Fisher’s test (APOE ε4 and Gender), t-test (age), and Chi square analyses
N number, CN cognitively normal, MCI mild cognitive impairment, AD Alzheimer’s disease, APOE ε4 apolipoprotein ε4 allele

displayed in Table 1. Comparing demographic and
clinical characteristics between diagnoses, AD participants were older than CN and MCI participants (AD:
75.0 [SD: 7.85], MCI: 75.6 [SD: 7.13], CN: 72.9 [SD:
6.12], p < 0.001) and were more likely to carry at least
one copy of APOE ε4 allele (AD: 71.1%, MCI: 46.8%,
HC: 28.1%, p < 0.001). As expected, the PHS were significantly higher in AD participants (AD: 0.847 [SD:
0.941], MCI: 0.415 [SD: 0.967], CN: 0.0271 [SD: 0.763],
p = 8.25e− 08). This result was consistent in the sub-population consisting of APOE ε4 carriers only (AD: 1.33
[SD: 0.62], MCI: 1.29 [SD: 0.66], CN: 1.04 [SD: 0.55],
p = 9.55e− 4). However, in the APOE ε4 non-carrier

subgroup, the difference of PHS across clinical classification was not seen (AD: -0.35 [SD: 0.31], MCI: -0.35
[SD: 0.34], CN: -0.37 [SD: 0.36], p = 0.895).
Association with cross‑sectional Aβ deposition

Using linear regression to evaluate the relationship
between PHS and Aβ burden at baseline, we found that
increased PHS values were associated with higher Aβ
deposition. Similar results were obtained when looking
at CL values specifically in the three areas investigated,
neocortical, frontal cortex and posterior cingulate, with
stronger effects systematically obtained in the posterior
cingulate region, followed by the frontal cortex and then

Table 2 Association between PHS and cross-sectional Aβ deposition
Population

N [CN/MCI/AD]

Region

beta

SE

CI 95%

FDR-adjusted p

Whole Cohort

780 [573/124/83]

neocortical

19.98

2.91

[14.3–25.7]

1.44E-10

posterior cingulate

25.54

3.61

[18.4–32.6]

7.41E-11

frontal cortex

21.19

3.15

[15.0–27.4]

2.51E-10

neocortical

25.28

4.00

[17.4–33.2]

5.17E-08

posterior cingulate

33.06

4.94

[23.3–42.8]

7.88E-09

frontal cortex

26.63

4.38

[18.0–35.3]

1.31E-07

neocortical

12.61

4.43

[3.90–21.3]

1.25E-02

posterior cingulate

14.28

5.53

[3.42–25.1]

2.43E-02

frontal cortex

13.62

4.77

[4.24–23.0]

1.25E-02

APOE ε4 carriers

APOE ε4 non carriers

278 [161/58/59]

502 [412/66/24]
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the neocortical region (Table 2). These results were consistent in the sub-populations composed exclusively of
APOE ε4 carriers and non-carriers, although with less
significant effects. We then used likelihood ratio tests to
determine if the addition of PHS and APOE ε4 status in a
model resulted in improvements in the fit. The addition
of APOE ε4 status (β = 39.5, SE = 2.8, p = 8.05e− 39) and
PHS (β = 24.2, SE = 1.55, p = 3.74e− 48), individually, both
resulted in statistically significant improvements from
a base model controlling for age, gender and education
only. However, the addition of PHS in a model already
controlling for APOE ε4 status was not significant in any
of the three areas investigated (frontal cortex, p = 0.066;
posterior cingulate, p = 0.1306; neocortical, p = 0.08).
Association with regional brain atrophy

In the linear-mixed effect analysis, PHS was significantly associated with cortical volume changes in most
regions of interest. The effects were strongest in regions
from the AD cortical signature, including temporal lobe,
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entorhinal cortex, posterior cingulate and precuneus.
The cortical atrophy was fastest in individuals with high
PHS (Fig. 1). However, when looking at non-ε4 carriers
only, none of the associations between PHS and cortical
atrophy remained significant after controlling for multiple comparisons. In addition, the effect sizes were considerably reduced (Supplementary Fig. 2).
Association with cognitive decline

In the linear mixed model analyses, we did not find
any significant association between PHS and cognitive
decline. The analyses were restricted to non-AD individuals (CN + MCI and CN only) and the results were consistent across the three cognitive domains investigated
(Table 3). Further, comparing individuals with high PHS
against low PHS, there was no significant difference in
rate of cognitive decline between the two groups. Likelihood ratio tests comparing linear-mixed effects models
with and without the PHS term, showed that the presence of PHS in the model resulted in minor improvement

Fig. 1 PHS is associated with local Aβ and cortical atrophy. Beta estimates of (A) the associations of PHS with cross-sectional voxel-wise CL and (B)
Longitudinal change in regional cortical volumes in individuals with high (1 SD above mean, ∼ 84 percentile) PHS

Table 3 Associations between PHS and cognitive decline
Population

N

Domain

beta

SE

CI 95%

p

CN + MCI

697

CDR SoB

0.004

0.014

[0.023–0.03]

0.747

Episodic Recall

0.007

0.011

[−0.014–0.028]

0.519

Executive Function

− 0.023

0.014

[− 0.05–0.003]

0.086

0.023

0.017

[−0.01–0.056]

0.174

Episodic Recall

0.001

0.013

[−0.024–0.026]

0.948

Executive Function

−0.018

0.015

[−0.047–0.011]

0.225

CN

573

CDR SoB
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in CDR-SB (X2 = 6.29, p = 0.043) and Episodic recall
(X2 = 6.58, p = 0.037). However, the addition of PHS did
not result in a better fit in the model predicting Executive
function (X2 = 2.83, p = 0.24).
Association with age of onset of abnormal levels of Aβ
deposition

The age of onset of individuals with a high PHS (> 1.04)
was significantly lower than individuals with a low PHS
(<− 0.67). The median age at which AIBL participants
with a high PHS reached abnormal levels of Aβ (Fig. 2)
was 67.6 years (CI 95% [65.6, 68.6]), 12.4 years earlier
than those with a low PHS (80 years, CI 95% [78.3, 82.4]).
The hazard ratio comparing the high PHS versus the
low PHS group was 3.9 (CI 95% [3.1, 4.9], log rank test
p = 3.72e− 17). Restricting this analysis to ε3/ε3 individuals
only, the high PHS group still had an earlier age of onset
(73.9 years, CI 95% [72.4, 78.2]) compared to the low PHS
population (82.4 years, CI 95% [76.8.4, 84.2]), with a hazard ratio of 1.8 (CI 95% [0.9, 3.2], log rank test p = 0.072).
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Discussion
Over the last decade, GWAS have clearly demonstrated
that common complex diseases are typically associated
with hundreds or thousands of genetic markers, collectively contributing to disease risk. This highly polygenic
underpinning has been utilised in PRS by aggregating the
effect of multiple genetic variants into a single score to
predict disease risk. PRS have shown predictive values in
several complex disorders, however, the approach does
not account for age of onset, which is critical for neurodegenerative disease such as AD. The recent development of polygenic hazard score overcomes this limitation
by predicting individuals’ age-specific risk of AD development [9]. In this study, we attempted to replicate the
findings from Tan et al. [19] and assess the utility of a
PHS in an independent cohort. While investigating the
relationship between PHS and cross-sectional Aβ deposition, we found that the PHS had slightly better predicting
capabilities than using APOE ε4 status alone. This result
was expected considering the effects of the APOE ε2 and

Fig. 2 Kaplan-Meier plot showing the age of onset, defined as the age at which individual reach an abnormal level of Aβ (CL ≥ 20). The population
was stratified by PHS, high (mean + 1 SD) versus low (mean – 1 SD). Shaded areas indicate 95% confidence intervals
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ε4 alleles were already accounted for in the calculation of
the PHS. However, the marginal improvement in models to predict Aβ deposition observed when using PHS,
suggests that the number of APOE ε4 alone can provide
comparable predictive information. The major contribution of APOE in the PHS definition is evident when looking at the stratified score distribution (Supplementary
Fig. 1). Individuals falling in the low PHS bracket (1 SD
below the mean) are all ε4 non-carriers, while all ε4/ε4
individuals, conversely, are found in the high PHS group
(1 SD above the mean). Nonetheless, we were able to find
associations between PHS and regional Aβ deposition
and brain atrophy in non-ε4 individuals. Although with
relatively small effect sizes, these associations are consistent with the findings reported by Tan et al. [19] and
support the claim that the PHS can provide predicting
capabilities beyond APOE status.
Investigating cognitive domains, we did not find any
evidence of association between PHS and longitudinal
cognitive decline. These analyses were performed on
non-demented individuals (N = 697) with a proportion
of 82% CN and 18% MCI. This ratio was very different
from the study cohort utilised in Tan et al., which consisted of about 36% CN and 64% MCI. Considering that
healthy individuals have a much less pronounced cognitive decline trajectory, the over-representation of CN
in our dataset could have impacted the results. Further,
the linear mixed model used in this study was slightly
different than the one presented in the original paper.
Specifically, we used the CL values instead of the frontal
florbetapir SUVR. Although, it is not expected that this
deviation would generate differing results, they could
have impacted and decreased the strength of the associations between PHS and cognitive decline.
Investigating the associations between PHS and age
of onset, we found that individuals with a high PHS had
a significantly younger age of onset (67.6 years) than
low PHS individuals (80 years). Among the APOE ε3/ε3
population, high PHS individuals had an expected age
of onset approximatively 8 years younger than low PHS
individuals. Although the difference was less noticeable
in the ε3/ε3 population, this result showed that the polygenic information, beyond the APOE ε4 allele, was useful
for predicting the age of disease onset.
Compared to traditional polygenic risk scores, which
provide a lifetime risk of developing a disease, the polygenic hazard scores provide prediction on age-specific
risk of disease development. This estimation of instantaneous risk for developing AD is valuable additional
information, as it could improve monitoring disease
progression and facilitate timely intervention. In this
study, we showed that the PHS had utility in predicting
abnormal Aβ deposition, brain atrophy and age of disease
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onset. However, the results suggested that APOE genotype alone could provide comparable predictive capabilities, suggesting that APOE remains the main component
of the PHS. This disproportionate contribution is mainly
due to the large weight attributed to APOE alleles, which
shadows the less extensive effects of the other diseaseassociated variants utilised in the score calculation. This
is the case in both PRS and PHS approaches and reflect
the difficulty in classifying AD genetic risk above and
beyond APOE ε4. Recent studies have suggested that
the use of less stringent significance threshold for SNPs
selection could results in better performing scores [7,
8, 24]. This strategy could potentially further improve
the prediction accuracy of the PHS. However, caution
must be taken as the inclusion of many SNPs could lead
to over-specification and result in a score that performs
poorly in other cohorts. Furthermore, in addition to nonmodifiable factors, PHS and PRS could both be enriched
with the introduction of lifestyle and environmental factors, known to be associated with the disease. Moving
forward, we can anticipate that combining genetic, lifestyle and environmental components will facilitate the
development of more refined and personalised risk profiles that will become relevant in clinical settings.

Supplementary Information
The online version contains supplementary material available at https://doi.
org/10.1186/s12864-022-08617-2.
Additional file 1: Supplementary Figure 1. A, Distribution of PHS in the
whole cohort. High and low PHS were defined as 1 SD above the mean and
1 SD below the mean respectively. B, Distribution of PHS stratified by number
of APOE e4 alleles (0 = e2/e3, e2/e2, e3/e3; 1 = e4/e3, e4/e2 ; 2 = e4/e4).
Additional file 2: Supplementary Figure 2. PHS is associated with local
Ab and cortical atrophy in non-ε4 carrier. Beta estimates of (A) the associations of PHS with cross-sectional voxel-wise Centiloid and (B) Longitudinal
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Additional file 3: Supplementary Table 1. Beta estimates of the interaction between PHS and time on longitudinal regional cortical volume
change controlling for APOE status.
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